Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleCurrent Practice

Answer: Answer to Ophthaproblem

Dominik W. Podbielski and Jason Noble
Canadian Family Physician October 2008; 54 (10) 1396-1398;
Dominik W. Podbielski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Noble
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

2. Wet age-related macular degeneration

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the Western world for those aged 50 years and older.1 It is associated with degenerative, oxidative, and inflammatory changes in the macular region of the retina, which can cause central visual loss. Age-related macular degeneration is categorized into 2 forms: a dry or nonneovascular form and a wet or neovascular form. The dry form is more common and accounts for the vast majority of ARMD cases. The wet form, however, is more debilitating, and is responsible for more than 80% of the visual loss in such patients.1 The prevalence of early ARMD increases from around 4% in those younger than 60 years to more than 30% in those aged 85 years and older.2 Known risk factors of ARMD include family history, increasing age, smoking, and white race. With an aging population, the prevalence and incidence for ARMD will increase and are predicted to pose an enormous challenge to the provision of eye care in Canada.3

Age-related macular degeneration is believed to result primarily from dysfunction in the retinal pigment epithelium—a critical layer underneath the retina, which is multifunctional and responsible for retinal health. Dry ARMD, characterized by drusen on direct ophthalmoscopy, might convert to wet ARMD acutely or subacutely. Wet ARMD refers to the development of neovascularization within the neural retina from vessels originating from the choriocapillaris, a complex network of blood vessels underlying the retina and retinal pigment epithelium. The new choroidal vessels cause vascular leakage and hemorrhaging, resulting in devastating visual loss.4

On ophthalmoscopy, wet ARMD is characterized by the presence of subretinal fluid, intraretinal hemorrhage within the macular region, and sometimes exudates (Figure 1). The other diagnoses in question were incorrect based on typical fundoscopy findings: Retinal detachment is diagnosed by an elevated translucent retina with no hemorrhage. Central retinal vein occlusion is characterized by the so-called blood-and-thunder picture, with cotton-wool spots, intraretinal hemorrhaging, and disc edema. A patient with diabetic retinopathy normally presents with microaneurysms, cotton-wool spots, and dot-blot hemorrhages throughout the retina.

Figure 1
  • Download figure
  • Open in new tab
Figure 1

Subretinal fluid, intraretinal hemorrhage within the macular region, drusen, and exudates consistent with wet age-related macular degeneration

Symptoms of wet ARMD include metamorphopsia, blurry vision, and central scotoma.4 On examination, vision can have decreased to 20/400 or worse. An Amsler grid (Figure 2) tests for macular function and can detect early changes from wet ARMD.

Figure 2
  • Download figure
  • Open in new tab
Figure 2

Amsler grid: the patient is asked to focus on the central dot and report whether any of the lines appear wavy, and whether any areas of the grid appear to be missing. This is useful in identifying ARMD and as a home test for monitoring changes

Management

Patients with moderate to advanced dry ARMD can decrease their chance of progression to wet ARMD with various methods. Dietary modification, with increased green leafy vegetable intake, and smoking cessation are important evidence-based lifestyle changes.5,6 Furthermore, supplementation with a multivitamin that combines high-dose vitamins C and E, β–carotene, and zinc, in accordance with the formula used in the Age-Related Eye Disease Study, can decrease the progression to the wet form of ARMD by up to 25% for those with intermediate to severe dry ARMD.7

If exudative ARMD is suspected, an urgent referral (ie, within 1 week) to an ophthalmologist is necessary.4 Diagnosis is determined by funduscopic examination combined with intravenous fluorescein angiography. Optical coherence tomography, a form of macular imaging, can also be obtained to assess for macular edema and to provide baseline data for assessment of response to therapy.

Treatment

In recent years, the treatment for wet ARMD has undergone revolutionary changes. Previous treatments, such as thermal laser photocoagulation and photodynamic therapy with verteporfin, were only partially effective at stabilizing vision and only seldom resulted in visual improvement. These treatments have now given way to inhibitors of vascular endothelial growth factor (VEGF), namely ranibizumab and bevacizumab.

At present, ranibizumab is the treatment of choice for exudative ARMD and has been approved by the Common Drug Review. It is currently covered only by the provincial health care systems in Quebec and Ontario, but is being considered for coverage in the provincial formularies of other provinces. In several large randomized controlled trials, ranibizumab has been shown to stabilize vision in more than 95% of patients with wet ARMD. Further, it is the first treatment that is associated with a statistically significant mean improvement in visual acuity in such patients.8,9

Bevacizumab has not been studied in similar randomized controlled trials but is often employed for cost reasons; each intravitreal ranibizumab is more than 50 times the price of intravitreal bevacizumab (which is prepared by a compounding pharmacy from vials prepared for intravenous administration).10

The anti-VEGF treatments are administered by injection into the vitreous cavity, using a sterile technique in an office setting. Patients typically require a minimum of 3 injections, with each injection separated by approximately 1 month. Patients are then closely monitored for treatment response and potential need for further treatments.

Most patients tolerate intravitreal injection of ranibizumab and bevacizumab very well and do not experience serious problems; however, local and systemic complications can occur. Serious ocular complications include endophthalmitis (< 0.2% per injection), retinal detachment (< 0.1% per injection), and traumatic cataract (< 0.1% per injection).8,9,11

The safety profile of ranibizumab has been documented during several randomized trials and includes risk of hypertension (4.33% to 16.77%), myocardial infarction (1.44% to 1.89%), and stroke or cerebral infarction (0.72% to 1.89%).8,11 Indeed, the manufacturer of ranibizumab has released statements warning of the potential increased risk of stroke with intravitreal injection.

The safety profile of intravitreal bevacizumab is not as well known. When given intravenously for colon cancer, bevacizumab has been shown to induce serious systemic problems, such as hypertension, bleeding, and thromboembolic events. Although it has been demonstrated that bevacizumab is detectable in serum after injection into the eye, the peak serum levels achieved are minuscule relative to the level attained during intravenous administration.9 Nevertheless, patients are theoretically at risk of the aforementioned adverse events documented with intravenous bevacizumab.

Recommendations

Patients with dry ARMD can benefit from a variety of lifestyle and nutritional measures to help prevent visual loss. Such patients should be encouraged to use an Amsler grid at home. Conversion to wet ARMD can manifest as acute visual loss with metamorphopsia or central scotoma. These patients should be referred to an ophthalmologist immediately for consideration of treatment with anti-VEGF agents.

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    ResnikoffSPascoliniDEtya’aleDKocurIPararajasegaramRPokharelGPGlobal data on visual impairment in the year 2002Bull World Health Organ2004821184451Epub 2004 Dec 14
    OpenUrlPubMed
  2. ↵
    WangJJRochtchinaELeeAJChiaEMSmithWCummingRGTen-year incidence and progression of age-related maculopathy: the blue Mountains Eye StudyOphthalmology20071141928
    OpenUrlCrossRefPubMed
  3. ↵
    CruessAZlatevaGXuXRochonSBurden of illness of neovascular age-related macular degeneration in CanadaCan J Ophthalmol200742683643
    OpenUrlCrossRefPubMed
  4. ↵
    Riordan-EvaPWhticherJPVaughan & Asbury’s general ophthalmology17New York, NYMcGraw-Hill2008
  5. ↵
    KhanJCThurlbyDAShahidHClaytonDGYatesJRBradleyMSmoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisationBr J Ophthalmol20069017580
    OpenUrlAbstract/FREE Full Text
  6. ↵
    ChongEWKreisAJWongTYSimpsonJAGuymerRHDietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysisArch Ophthalmol2008126682633
    OpenUrlCrossRefPubMed
  7. ↵
    Age-Related Eye Disease Study Research GroupA randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8Arch Ophthalmol200111910141736
    OpenUrlCrossRefPubMed
  8. ↵
    BrownDMKaiserPKMichelsMSoubraneGHeierJSKimRYRanibizumab versus verteporfin for neovascular age-related macular degenerationNew Engl J Med200635514143244
    OpenUrlCrossRefPubMed
  9. ↵
    AndreoliCMMillerJWAnti-vascular endothelial growth factor therapy for ocular neovascular diseaseCurr Opin Ophthalmol20071865028
    OpenUrlCrossRefPubMed
  10. ↵
    RafteryJPLoteryAThe cheaper drug, bevacizumab, should be referred to NICEBMJ200733475903812
    OpenUrlFREE Full Text
  11. ↵
    RosenfeldPJBrownDMHeierJSBoyerDSKaiserPKChungCYRanibizumab for neovascular age-related macular degenerationNew Engl J Med200635514141931
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 54 (10)
Canadian Family Physician
Vol. 54, Issue 10
1 Oct 2008
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Answer: Answer to Ophthaproblem
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Answer: Answer to Ophthaproblem
Dominik W. Podbielski, Jason Noble
Canadian Family Physician Oct 2008, 54 (10) 1396-1398;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Answer: Answer to Ophthaproblem
Dominik W. Podbielski, Jason Noble
Canadian Family Physician Oct 2008, 54 (10) 1396-1398;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • 2. Wet age-related macular degeneration
    • Management
    • Treatment
    • Recommendations
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Question: Can you identify this condition?
  • Google Scholar

Cited By...

  • Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
  • Google Scholar

More in this TOC Section

Current Practice

  • Intraprofessional relationships
  • Scurvy
  • Lyme disease
Show more Current Practice

Ophthaproblem

  • Answer: Can you identify this condition?
  • Question: Can you identify this condition?
  • Question: Can you identify this condition?
Show more Ophthaproblem

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire